GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines through its TFome^TM (Transcription-Factor-ome) induced pluripotent stem cell (iPSC) programming platform that enables expansion into in vivo rejuvenation and reprogramming, today announced the appointment of Stefan Irion, MD,  as chief scientific officer.

GC Therapeutics, Inc. (GCTx), a biotechnology company created to scale and unlock the next generation of cell therapy-based medicines through its TFome™ cellular programming platform, today announced a series of corporate and pipeline updates.

GC Therapeutics (GCTx), a biotechnology company with the mission to enable scalable, low-cost, and accessible human cell therapies for all patients, today announced a major advance in cell programming through the systematic, empirical exploration of transcription factor (TF) combinations to drive cell fates.

GC Therapeutics (GCTx), a pioneering biotechnology company advancing groundbreaking iPSC-based cell therapies, today announced the appointment of two industry leaders to its executive team.

TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines development and accelerates pipeline of potential best-in-class cell therapies across diverse therapeutic areas 

Amgen awarded GCTx Golden Tickets, which provide lab space at Lab Central (Cambridge, MA) and access to Amgen’s expertise in drug development

YEi Start in France is an accelerator program for science-based startup companies